BIOMAT Database Logo BIOMAT Database Logo

Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan. 2005

Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli

UI MeSH Term Description Entries
D008297 Male Males
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077146 Irinotecan A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin,CPT 11,CPT-11,Camptosar,Camptothecin-11,Irinotecan Hydrochloride,Irrinotecan,NK012 Compound,SN 38,SN 38 11,SN-38,SN-38-11,7 Ethyl 10 hydroxycamptothecin,CPT11,Camptothecin 11,SN3811
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's

Related Publications

Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
December 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
March 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.
August 2010, Journal of acquired immune deficiency syndromes (1999),
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
April 1998, Clinical pharmacology and therapeutics,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
April 2019, Antimicrobial agents and chemotherapy,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.
December 2015, The American journal of tropical medicine and hygiene,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
January 2010, Antiviral therapy,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
July 2021, Journal of Zhejiang University. Science. B,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
January 2013, PloS one,
Giuseppe Corona, and Emanuela Vaccher, and Giulio Cattarossi, and Ivana Sartor, and Giuseppe Toffoli
Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
June 2007, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!